Korean J Androl.  2005 Dec;23(3):116-121.

The Analysis of Preference for Three PDE-5 Inhibitors

• Yoon CJ
• Lee SH
• Moon KH
• Yoo ES
• Park JS
• Lee KS
• Shin HC
• Lee YW

Abstract

PURPOSE
To evaluate the preference factors for the treatment of erectile dysfunction (ED) with three different kinds of PDE-5 inhibitors.
MATERIALS AND METHODS
This prospective, open-label study recruited 140 patients from 5 medical centers and urological clinics in the Daegu and Gyeongbuk area of South Korea. All patients underwent sildenafil, tadalafil, and vardenafil therapy with at least four attempts at sexual intercourse for each medication. There was a 1-week drug washout period following each medication period. Patients were asked to state their preference among the three medications.
RESULTS
The mean age of the 140 patients was 50.9 years. Most patients had mild-to-moderate ED(57 patients, 40.7%) and moderate ED(47 patients, 33.6%), the remaining patients had mild(23 patients, 16.4%) or severe ED (13 patients, 9.3%). Of 140 evaluated patients, 58(41.3%) patients preferred treatment with tadalafil, compared with 39(28.1%) with sildenafil and 37(26.6%) with vardenafil. When grouped by age, tadalafil was most preferred by men in their 30s and 40s(42.9%, 57.5%), sildenafil was preferred by those in their 50s(48.3%), and vardenafil was preferred by those in their 60s(51.6%). The reasons for specific preferences were prolonged erectile function (68.0%) and good erectile function(66.0%) for tadalafil, good erectile function (88.2%) for the sildenafil, and good rigidity of the erect penis(59.4%) for vardenafil.
CONCLUSIONS
Tadalafil was most preferred among the phosphodiesterase inhibitors, but the preference rates varied for men of different ages. All the medications were well tolerated.

Keyword

Erectile dysfunction; Phosphodiesterase-5 inhibitors; Patient preference

MeSH Terms

Coitus
Daegu
Erectile Dysfunction
Gyeongsangbuk-do
Humans
Korea
Male
Patient Preference
Phosphodiesterase 5 Inhibitors*
Phosphodiesterase Inhibitors
Prospective Studies
Sildenafil Citrate
Tadalafil
Vardenafil Dihydrochloride
Phosphodiesterase 5 Inhibitors
Phosphodiesterase Inhibitors